Member Info for Early_Bird

A reminder to Mr Beeston on how bullish he was pre suspension: https://youtu.be/h9VecuNbnYY nearly 6 months of suspension later still nothing... Not quite what was promised in this vid but hey ho this is AIM and directors lie through their front teeth more often than not. Hope for all honest PIs this comes good... have a good amount of money locked in here myself.

Here's to a good week next week. Think the penny might be dropping finally here on what a fantastic & totally unique opportunity this share is.

still holding all my shares here and absolutely no doubt in my mind this will be a sensational performer medium to long term as well as short term at these stupid prices. You wait until the takeout offers start coming in...

Sooner this is back over 24p IPO price the better. These prices are an absolute give away.

at current levels.. think this will bounce v strongly when news starts landing.

SmudgeDan is a maestro at picking under the radar stocks with huge upside.

confusing as feck to buy. The price shown on here is in $ and cents... when you go to buy you will be quoted in GBP or pence.. so you have to do the currency conversion yourself to work out what pruice you are getting. Managed to pick a few up before the bell. Should be a strong day tomorrow.

Agreed Gary. Volume hasn't been very large since listing so sellers most likely to be bored PIs who expected quick buck. This is a 1-3 year hold for me, only LT hold in the PF and when the selling pressure has dried up and dust has settled I will look to add another chunk here. Movement thus far entirely predictable. Traction here will start when newsflow starts, I can personally see a Nasdaq listing application in the not too distant future which would get things moving significantly. I'm interested in how they are going to market the EU approved Episalvan for partial thickness wounds... Mr Sudocrem is on board so product placement and marketing surely there is scope to develop a product that targets a wider audience than just your average prescription gel for burns? Episalvan accelerates healing so why not create a product similar to sudocrem? One question id like to ask... Anyone attend their recent presentation?

I have re taken a position here over the past month or so as believe the company at £3m MC to be undervalued based upon the conservative 2016 EBITDA of £500k. I await the Q1 trading update here, if the directors prove that they are following their mantra to under promise and over deliver in their Q1 numbers and it looks as if £500k EBITDA will be exceeded then I will look to double up my holding here. The ball is firmly in their court. GLA

How exciting. My largest holding and my only LT hold in the PF with 1-3 year view here. Look forward to being a part of the story here as it unfolds. GLA

We are officially AMYT! Trading to resume tomorrow

Harry Stratford - founder of FTSE 100 giant Shire Plc (LON:SHP), who set also set up ProStrakan. Shire being the world’s largest speciality pharma company. Joe Wiley - previously led the European office of life sciences venture capital firm Soffinova Ventures. Ray Stafford - was chairman, chief executive and majority shareholder of the Tosara Group, which owned, manufactured and marketed Sudocrem. Tosara was later sold to the American company Forest Laboratories, where he became executive vice president for global marketing. Michele Bellandi - former Head of Commercial for Europe at Shire. Find me a better BOD on AIM.

and another http://www.proactiveinvestors.com/companies/news/124240/fastnet-equity-plc-unveils-transformational-drugs-deal-124240.html

My shares here are firmly in the bottom drawer. Board of directors assembled just about the best you could possibly come across on AIM unlike 99% of shares on AIM I'm willing to trust this bunch to deliver massive shareholder returns in the short medium and long term. Find me another share on AIM that's has a drug that's has passed phase 3 trials and has been EU approved for marketing for a MC £50M. You wont because they are all over £500m-1bn. Get this this Phase 3 trial approved for treatment of EB (no other treatment on the market) and that's precisely the sort of valuation we will be looking at and this trial is expected to start in H2. As we already have Episalvan approved phase 3 for partial skin thickness wounds it is tipped to do very well in this next trial.

http://www.*************.com/views/19788/fastnet-a-cracking-rto-completed-we-are-well-up-on-this-share-tip-more-to-go

on AIM with a phase 3 approved drug with EU approval ready for marketing at £50M MC... the rest are only just starting lengthy phase 3 trials that are years away... The next set of phase 3 trials here are for Episalvan approval in treatment of the rare disease "EB" for which there is currently no effective treatment hence the huge opportunity. The fact that Episalvan is already Phase 3 approved for partial thickness wounds means its trials for EB (starting in H2) will not be lengthy and very likely to be approved. So we can soon start marketing Episalvan as a treatment for partial thickness wounds on the side to this huge potential game changing EB trial. If approved then its a total game changer and this will unleash the huge £100M+ per annum cashflows and therefore warrant £1b+ MC If you look at the directors involved and the amount they have put on the line here (buying 30% of the co.) join the dots you have something really very exciting here.

€10,000,000 on receipt of first marketing approval by the EMA of Episalvan (which is payabe on Admission, as this has been received); •e ither (1) €5,000,000 once net exfactory sales of Episalvan have been at least €100,000 or (ii) if no commercial sales are made within 24 months of EMA first marketing approval €2,000,000 24 months after receipt of such approval and €3,000,000 following the first commercial sale; • €10,000,000 once net exfactory sales/net revenue in any calendar year exceed €50,000,000; • €15,000,000 once net exfactory sales/net revenue in any calendar year exceed €100,000,000; • €10,000,000 on receipt of marketing approval by the EMA or FDA of the orphan drug product containing betulin as its API for the treatment of Epidermolysis Bullosa; So its 10m euro payable on the approval and the rest of the royalties relate to cashflow which -by the way- is serious serious cashflow of 100 million euros per anum. Think about it. Once we are achieveing 100m euros per anum cashflow what is a tiny 10m euro payment? Our market cap by then will be over £1billion I'm very excited.

That's the game changer mate... if we get Episalvan approved for EB then this is heading to the moon as currently no drug out there that deals with this rare disease and its essentially $1.5b per anum cashflow for us. That's buyout teritory by the major players for a lofty sum. We have Episalvan already EU approved for skin thickness wound treatment which will get revenue started on this, these Phase III trials for EB however are the real game changer. V v exciting.

http://www.fastnetequity.com/~/media/Files/F/Fastnet-Oil-and-Gas/circulars/amryt-admission-document.pdf Very exciting read. Still digesting, peer comparison of other companies in similar stages of orphan drug development at in the hundreds of millions to billions market cap range. Of course further funds will be required, this is a pharma company developing a drug for market. Management team have to be the best out there across all AIM pharma companies! Some very impressive reading. EIS approved too! This is one for the ISA/pension fund IMO think it could be life changing over the course of the next few years.

Total and utter no brainer for me buying in at these levels. Directors have snapped up 30% of Amryt Pharma PLC. thats a huge sign of confidence.